McCollum Christoferson Group LLC Cuts Position in Abbott Laboratories $ABT

McCollum Christoferson Group LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 60.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 40,581 shares of the healthcare product maker’s stock after selling 62,644 shares during the period. McCollum Christoferson Group LLC’s holdings in Abbott Laboratories were worth $3,682,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ABT. J. Stern & Co. LLP increased its position in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after buying an additional 39,005,451 shares in the last quarter. Norges Bank bought a new stake in Abbott Laboratories in the fourth quarter worth $2,938,892,000. Arrowstreet Capital Limited Partnership grew its stake in shares of Abbott Laboratories by 217.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock worth $566,967,000 after acquiring an additional 3,780,402 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Abbott Laboratories by 303.0% in the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after acquiring an additional 3,330,368 shares during the last quarter. Finally, Ninety One UK Ltd bought a new position in shares of Abbott Laboratories during the fourth quarter valued at $336,815,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Up 1.1%

Abbott Laboratories stock opened at $110.92 on Thursday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The business’s fifty day moving average is $96.86 and its 200 day moving average is $99.73. The stock has a market capitalization of $191.93 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 2.12 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ABT. JPMorgan Chase & Co. upped their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Jefferies Financial Group reduced their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Evercore decreased their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Sanford C. Bernstein dropped their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $118.17.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Bank of America issues a Buy rating: The endorsement from Bank of America Securities adds to positive Wall Street sentiment and may support investor confidence in Abbott’s earnings and growth outlook. Abbott Laboratories Receives a Buy from Bank of America Securities
• Positive Sentiment: Abbott and Google expand glucose-monitoring partnership: Abbott will integrate Lingo glucose data with Google’s AI-driven consumer health tools. The companies also plan a large real-world metabolic-health study, potentially improving personalized coaching, supporting future Lingo features and increasing the commercial value of Abbott’s biowearable platform. Abbott Laboratories Ties Lingo Glucose Data to AI Health Tools
• Positive Sentiment: Potential cardiovascular innovation: Abbott’s ongoing PULSE study is evaluating early treatment for atrial fibrillation. Positive results could strengthen Abbott’s electrophysiology portfolio, although the study remains a longer-term catalyst and does not yet establish a commercial benefit. Early AF Treatment on Trial: What Abbott’s PULSE Study Could Mean for Investors
• Neutral Sentiment: Blood-donation campaign returns: Abbott and the Big Ten revived the “We Give Blood” campaign amid a U.S. blood shortage. The initiative enhances Abbott’s public profile and reinforces its healthcare mission, but it is unlikely to have a material near-term effect on earnings. Abbott and Big Ten Bring Back We Give Blood

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.